Displaying drugs 1426 - 1450 of 2353 in total
Vorsetuzumab mafodotin
Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
Investigational
Matched Description: … Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 …
JNJ-75276617
JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies).
Investigational
SKF-96365 free base
SKF-96365 is a receptor-mediated calcium entry (RMCE) inhibitor structurally different from other calcium antagonists.
Investigational
Trotabresib
Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
Investigational
SNX-2112
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
Investigational
Matched Description: … SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.[A253137] …
RO7502175
Investigational
Sennosides
Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label] and empty the large intestine before surgery. The medication is taken by mouth or via the rectum[FDA Label]. It typically begins working in minutes when given by rectum and within twelve hours when given...
Experimental
Matched Iupac: … 4,4'-dihydroxy-10,10'-dioxo-5,5'-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})-9H,9'H,10H,10 …
Matched Products: … X-M SOLUSYON PURGATIF 75 ML ... X-M DİET 1,5 MG/ML ÇÖZELTİ, 75 ML …
Matched Products: … X-M SOLUSYON PURGATIF 75 ML ... X-M DİET 1,5 MG/ML ÇÖZELTİ, 75 ML …
Pemtumomab
Pemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. It targets the mucin 1 (MUC1) protein.
Investigational
Matched Description: … Pemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. …
9CUAB30
9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among others.
Investigational
Matched Description: … 9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu …
BC9KBY85WY
Investigational
PG-530742
PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Investigational
CP-122721
CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Investigational
Tanespimycin
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
Investigational
Matched Iupac: … tetramethyl-20,22-dioxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21),2,4,6,10,18-hexaen-9- …
Matched Description: … manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 …
Matched Description: … manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 …
Enokizumab
A humanized immunoglobulin G1k anti-interleukin-9 mAb.
Investigational
Matched Description: … A humanized immunoglobulin G1k anti-interleukin-9 mAb. …
Molybdate Mo-99
Experimental
Andecaliximab
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Investigational
Matched Description: … Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). ... clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 …
Calcium
Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the...
Nutraceutical
Matched Mixtures name: … Mega-vim 75 With Beta-carotene - Tablets ... Mega-vim 75 With Beta-carotene - Tablets ... CALCIA TABLET, 90 ADET …
PF-06273340
Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).
Investigational
Matched Description: … Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 …
CTCE-9908
Investigational
Denecimig
Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9.
Investigational
Matched Description: … Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9. …
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Matched Description: … LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9. …
Pexelizumab
Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.
Investigational
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 …
Elraglusib
Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).
Investigational
Matched Description: … Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis …
Vidutolimod
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Investigational
Matched Description: … Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine. …
Displaying drugs 1426 - 1450 of 2353 in total